MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why BGMS Stock dropped -9.79% Today — RQD Quant Desk Flash
$0.83 -9.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.81
Bio Green Med Solution Inc. (BGMS) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $5.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.81 (-1.95%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGMS)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY BGMS SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.85+7.1% Next Q
48
Q2 (-2Q)Grade D$0.91+5.5% Next Q
45
Q3 (-1Q)Grade D$0.96-13.5% Next Q
43
CurrentGrade D-$0.83-7.4% Hist 90D α
40
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BGMS Turnaround Squeeze
While BGMS currently carries a cautious 40/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.90) and Max Pain ($0.87) forces dealer call-delta covering toward $2.94.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BGMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BGMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BGMS Stock dropped -9.79% Today — RQD Quant Desk Flash
Bio Green Med Solution Inc. (BGMS) dropped -9.79% to $0.83, trading at 12% of its 52-week range ($0.57 – $2.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($0.57 – $2.8) with RSI-14 at 49 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.83 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BGMS Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGMS)
- ✓Walkthrough of BGMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BGMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.43%📐 HORIZONTAL RANGE
2026-10-30O $0.90H $0.92L $0.83C $0.83VOL 11.5K
RES: $1.17SUP: $0.58SMA50: $0.90SMA200: $0.97
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BGMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BGMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BGMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BGMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGMS)
Health Care Rank #655 of 1016
⚔️ GELS vs BGMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BGMS vs. GELS, LGVN, PCSA, SCNX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bio Green Med Solution Inc. (BGMS) ranks #655 by composite RQD confidence (40/100, grade D-) and #937 by equity capitalization ($5.5M). Within this direct 5-issuer industry benchmark cohort, BGMS leads on earnings valuation at N/A trailing P/E, while BGMS leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BGMS at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BGMS
ACTIVE
Bio Green Med Solution Inc. | D- | 40/100 | — | — | -35.0% | -9.79% | $5.5M | Benchmark Subject |
| GELS Gelteq Limited | C- | 59/100 | — | — | — | +5.11% | $5.4M | /gels-vs-bgms → |
| LGVN Longeveron Inc. (Class A) | E | 32/100 | — | 67.0% | -35.0% | -1.68% | $5.6M | /lgvn-vs-bgms → |
| PCSA Processa Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.16% | $5.3M | /pcsa-vs-bgms → |
| SCNX Scienture Holdings Inc. | D- | 42/100 | — | 76.8% | -35.0% | +2.65% | $5.7M | /scnx-vs-bgms → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001130166In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bio Green Med Solution Inc. (BGMS) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $43.0K ) , GAAP net income of -$3.0M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+40.3% YoY). On the balance sheet, BGMS closed FY2025 with $8.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$3.0M | -$4.8M | -$4.8M | $8.2M | — |
| FY2024 (FY) | 2024-12-31 | $43.0K | -$11.2M | -$8.0M | -$8.0M | $4.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | $22.6M | -$16.1M | -$16.1M | — | — |
3. BGMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BGMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Bio Green Med Solution Inc. (NASDAQ: BGMS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.83 (-9.79% 1D, market cap $5.5M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BGMS ranks #655 in composite RQD confidence.
How does BGMS compare to GELS and LGVN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BGMS carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GELS (Gelteq Limited) holds a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $5.4M) and LGVN (Longeveron Inc. (Class A)) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $5.6M). Among the 5-stock peer group, BGMS leads on earnings multiple (N/A) while BGMS leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BGMS?
Per BGMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001130166), Bio Green Med Solution Inc. generated $0 in revenue (-100.0% YoY), -$3.0M in net income, and -$4.8M in free cash flow against $8.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BGMS trading relative to its 50-day, 200-day, and 52-week technical levels?
BGMS last traded at $0.83 (-9.79% on volume of 20,250 shares), positioning the stock -7.78% below its 50-day simple moving average ($0.90) and -14.43% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.57 to $2.80, BGMS sits at the 11.7% percentile with a 14-day RSI of 49.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.93).
BGMS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BGMS stock moving today?
Why BGMS Stock dropped -9.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.